Tirzepatide injection becomes the first medication authorized in Canada for moderate to severe OSA, demonstrating significant reductions in breathing disruptions in clinical trials.

A personal story explores why women with cardiovascular disease deserve earlier conversations about sleep-disordered breathing.

Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, securing a portfolio of clinical-stage orexin receptor 2 agonists. This strategic move aims to accelerate the development of new treatments...

Survey findings suggest fatigue remains widespread and debilitating across narcolepsy and idiopathic hypersomnia, even among patients taking medications.

Phase 3 TRIUMPH-1 trial data show retatrutide reduced the AHI by up to 36.1 events per hour alongside substantial weight loss.

The agency cited the manufacturer for distributing new sleep sack sizes and a clinical bassinet bundle without required clearance, alongside quality system and reporting violations.

A new study reveals that a new barrier has overtaken stress as the primary barrier to sleep for Gen Z.

People with narcolepsy and idiopathic hypersomnia often make it to work—but cognitive symptoms can keep them from performing at their best, according to a new survey .

The late-stage pharmaceutical company announces a leadership transition as it prepares for the potential commercialization of its once-daily oral therapy for obstructive sleep apnea.

The FDA-cleared device is designed to be a compatible platform to support future accessories.